Siegfried Release: Management Change In Global Technical Operations
(SIX: SFZN) The Siegfried Group announces a change in its Executive Committee. Walter
Kittl (1956), for five years Head Global Technical Operations and member of Siegfried‘s Executive
Committee, has decided to step down from his operational responsibility. He will
remain linked to Siegfried as a consultant.
He will be succeeded by René Imwinkelried, currently Head Research & Development. The new Head of Research & Development will be appointed in due course.
The Siegfried Group would like to express its gratitude to Walter Kittl for his enduring and successful commitment to the company and his exceptional contribution toward implementing the Transform strategy.
About Siegfried
The Siegfried Group is active worldwide in the field of Life Sciences with production facilities located in Switzerland, the USA, Malta, China, Germany and France. Siegfried reported annual sales of CHF 481 million for 2015 and employs approximately 2300 employees at nine locations on three continents. Siegfried Holding AG is listed on the SIX Swiss Exchange (SIX: SFZN).
Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding intermediates and controlled substances, and provides development and production services for finished dosage forms including sterile filling.
He will be succeeded by René Imwinkelried, currently Head Research & Development. The new Head of Research & Development will be appointed in due course.
The Siegfried Group would like to express its gratitude to Walter Kittl for his enduring and successful commitment to the company and his exceptional contribution toward implementing the Transform strategy.
About Siegfried
The Siegfried Group is active worldwide in the field of Life Sciences with production facilities located in Switzerland, the USA, Malta, China, Germany and France. Siegfried reported annual sales of CHF 481 million for 2015 and employs approximately 2300 employees at nine locations on three continents. Siegfried Holding AG is listed on the SIX Swiss Exchange (SIX: SFZN).
Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding intermediates and controlled substances, and provides development and production services for finished dosage forms including sterile filling.